Department of Public Health Programmes, Randers Regional Hospital, Central Denmark Region, Randers NØ, Denmark.
Department of Public Health Programmes, Randers Regional Hospital, Central Denmark Region, Randers NØ, Denmark.
Gastroenterology. 2018 Jul;155(1):99-106. doi: 10.1053/j.gastro.2018.03.062. Epub 2018 Apr 5.
BACKGROUND & AIMS: Most studies of the effectiveness of screening for colorectal cancer (CRC) using the fecal occult blood test tested the guaiac fecal occult blood test. However, the fecal immunochemical test (FIT) is now commonly used in screening. We aimed to evaluate the effectiveness of FIT-based screening for CRC on the number of incident CRC diagnoses and stage at diagnosis for individuals in Denmark who were invited for screening vs not yet invited.
We collected data for this register-based retrospective cohort study during the first 16 months of the prevalence round of a FIT-based CRC screening program (March 1, 2014 through June 30, 2015). A total of 402,826 residents of Denmark (50-72 years old) were randomly invited to undergo CRC screening within the study period, and 956,514 were invited thereafter. We obtained information on CRC diagnosis, date, and stage at diagnosis from the Danish Colorectal Cancer Group database. Cancer incidence per 100,000 invited/not yet invited individuals was calculated, along with the relative risk (RR) of CRC among invited compared with not yet invited individuals.
CRC incidence during the study period was 339.4/100,000 invited individuals and 169.6/100,000 not yet invited individuals. CRC incidence increased with age among invited and not yet invited individuals. For invited women compared with not yet invited women, the RR of being diagnosed with stage I CRC was 3.39 (95% CI, 2.61-4.39), with stage II CRC was 2.16 (95% CI, 1.71-2.72), with stage III CRC was 1.37 (95% CI, 1.08-1.75), and with stage IV CRC was 0.92 (95% CI, 0.68-1.23). For invited men compared with not yet invited men, the RR of being diagnosed with stage I CRC was 3.71 (95% CI, 2.97-4.64); with stage II CRC was 2.26 (95% CI, 1.84-2.77), with stage III CRC was 1.88 (95% CI, 1.53-2.30), and with stage IV CRC was 1.20 (95% CI, 0.95-1.52).
In analyzing data from a register-based cohort study in Denmark, we found that inviting individuals to undergo FIT-based CRC screening led to detection of almost 2-fold more cases of CRC than not inviting participants. The significant increase of CRC incidence among those invited for screening indicates a need for awareness of treatment capacity in countries introducing FIT-based CRC screening.
大多数关于使用粪便潜血试验(FOBT)进行结直肠癌(CRC)筛查效果的研究都检测了愈创木脂粪便潜血试验(gFOBT)。然而,粪便免疫化学试验(FIT)现在常用于筛查。我们旨在评估在丹麦,对受邀进行筛查的个体与尚未受邀进行筛查的个体相比,基于 FIT 的 CRC 筛查对 CRC 诊断的新发病例数量和诊断时的分期的有效性。
我们在基于 FIT 的 CRC 筛查计划的流行期第一轮(2014 年 3 月 1 日至 2015 年 6 月 30 日)的最初 16 个月内收集了这项基于登记的回顾性队列研究的数据。丹麦共有 402826 名 50-72 岁的居民在研究期间被随机邀请进行 CRC 筛查,此后有 956514 人被邀请。我们从丹麦结直肠癌组数据库中获得了 CRC 诊断、日期和诊断时分期的信息。计算了每 100000 名受邀/未受邀个体的 CRC 发病率,以及受邀个体与未受邀个体相比 CRC 的相对风险(RR)。
研究期间,受邀个体的 CRC 发病率为 339.4/100000 人,未受邀个体的 CRC 发病率为 169.6/100000 人。受邀和未受邀个体的 CRC 发病率随年龄增长而增加。与未受邀女性相比,受邀女性诊断为 I 期 CRC 的 RR 为 3.39(95%CI,2.61-4.39),II 期 CRC 为 2.16(95%CI,1.71-2.72),III 期 CRC 为 1.37(95%CI,1.08-1.75),IV 期 CRC 为 0.92(95%CI,0.68-1.23)。与未受邀男性相比,受邀男性诊断为 I 期 CRC 的 RR 为 3.71(95%CI,2.97-4.64);II 期 CRC 为 2.26(95%CI,1.84-2.77),III 期 CRC 为 1.88(95%CI,1.53-2.30),IV 期 CRC 为 1.20(95%CI,0.95-1.52)。
在分析丹麦基于登记的队列研究数据时,我们发现邀请个体进行基于 FIT 的 CRC 筛查可导致比不邀请参与者多近 2 倍的 CRC 病例被检出。受邀进行筛查的个体 CRC 发病率的显著增加表明,在引入基于 FIT 的 CRC 筛查的国家,需要意识到治疗能力的限制。